SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-315829"
 

Search: onr:"swepub:oai:DiVA.org:uu-315829" > Allogeneic Transpla...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Cornell, Robert F.Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA. (author)

Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma

  • Article/chapterEnglish2017

Publisher, publication year, extent ...

  • Elsevier BV,2017
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-315829
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-315829URI
  • https://doi.org/10.1016/j.bbmt.2016.10.010DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:134977299URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) is characterized by lymphoplasmacytic proliferation, lymph node and spleen enlargement, bone marrow involvement, and IgM production. Treatment varies based on the extent and biology of disease. In some patients, the use of allogeneic hematopoietic cell transplantation (alloHCT) may have curative potential. We evaluated long-term outcomes of 144 patients who received adult alloHCT for WM/LPL. Data were obtained from the Center for International Blood and Marrow Transplant Research database (2001 to 2013). Patients received myeloablative (n = 67) or reduced-intensity conditioning (RIC; n = 67). Median age at alloHCT was 53 years, and median time from diagnosis to transplantation was 41 months. Thirteen percent (n = 18) failed prior autologous HCT. About half (n = 82, 57%) had chemosensitive disease at the time of transplantation, whereas 22% had progressive disease. Rates of progression-free survival, overall survival, relapse, and nonrelapse mortality at 5 years were 46%, 52%, 24%, and 30%, respectively. Patients with chemosensitive disease and better pretransplant disease status experienced significantly superior overall survival. There were no significant differences in progression-free survival based on conditioning (myeloablative, 50%, versus RIC, 41%) or graft source. Conditioning intensity did not impact treatment-related mortality or relapse. The most common causes of death were primary disease and graft-versus-host disease (GVHD). AlloHCT yielded durable survival in select patients with WM/LPL. Strategies to reduce mortality from GVHD and post-transplant relapse are necessary to improve this approach.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Bachanova, VeronikaUniv Minnesota, Med Ctr, Bone & Marrow Transplant Program, Minneapolis, MN 55455 USA. (author)
  • D'Souza, AnitaMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (author)
  • Woo-Ahn, KwangMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA. (author)
  • Martens, MichaelMed Coll Wisconsin, Dept Oncol, Milwaukee, WI 53226 USA. (author)
  • Huang, JiaxingMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (author)
  • Al-Homsi, A. SamerSpectrum Hlth, Blood & Marrow Transplant, Grand Rapids, MI USA. (author)
  • Chhabra, SaurabhMed Univ South Carolina, Dept Med, Charleston, SC USA. (author)
  • Copelan, EdwardCarolinas HealthCare Syst, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA. (author)
  • Diaz, Miguel-AngelHosp Infanta Univ Nino Jesus, Dept Hematol Oncol, Madrid, Spain. (author)
  • Freytes, Cesar O.Texas Transplant Inst, San Antonio, TX USA. (author)
  • Gale, Robert PeterImperial Coll London, Dept Med, Div Expt Med, Hematol Res Ctr, London, England. (author)
  • Ganguly, SiddharthaUniv Kansas, Med Ctr, Blood & Marrow Transplantat, Div Hematol & Oncol, Kansas City, KS 66103 USA. (author)
  • Hamadani, MehdiMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (author)
  • Hildebrandt, GerhardUniv Kentucky, Div Hematol & Blood & Marrow Transplantat, Markey Canc Ctr, Lexington, KY USA. (author)
  • Kamble, Rammurti T.Baylor Coll Med, Div Hematol & Oncol, Ctr Cell & Gene Therapy, Houston, TX 77030 USA. (author)
  • Kharfan-Dabaja, MohamedH Lee Moffitt Canc & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA. (author)
  • Kindwall-Keller, TamilaUniv Virginia Hlth Syst, Div Hematol Oncol, Charlottesville, VA USA. (author)
  • Lazarus, Hillard M.Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA. (author)
  • Marks, David I.Univ Hosp Bristol NHS Trust, Adult Bone Marrow Transplant, Bristol, Avon, England. (author)
  • Nishihori, TaigaH Lee Moffitt Canc & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA. (author)
  • Olsson, Richard F.Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Div Therapeut Immunol, Dept Lab Med, Stockholm, Sweden.(Swepub:uu)riols677 (author)
  • Saad, AymanUniv Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA. (author)
  • Usmani, SaadCarolinas HealthCare Syst, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA. (author)
  • Vesole, David H.Hackensack UMC, John Theurer Canc Ctr, Hackensack, NJ USA. (author)
  • Yared, JeanUniv Maryland, Dept Med, Blood & Marrow Transplantat Program, Div Hematol Oncol,Greenebaum Canc Ctr, Baltimore, MD 21201 USA. (author)
  • Mark, TomerWeill Cornell Med Coll, Dept Med, New York, NY USA. (author)
  • Nieto, YagoUniv Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA. (author)
  • Hari, ParameswaranMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. (author)
  • Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA.Univ Minnesota, Med Ctr, Bone & Marrow Transplant Program, Minneapolis, MN 55455 USA. (creator_code:org_t)

Related titles

  • In:Biology of blood and marrow transplantation: Elsevier BV23:1, s. 60-661083-87911523-6536

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view